ID

26064

Beskrivning

Exclusion Criteria 1 Ropinirole Case Report Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Nyckelord

Versioner (1)
  1. 2017-10-05 2017-10-05 -
Rättsinnehavare

gsk

Uppladdad den

5 oktober 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

  • Senaste
  • Äldsta
  • Önskad
  • Senaste
    • Senaste
    • Äldsta
    • Önskad

Inga kommentarer

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Exclusion Criteria 1 Ropinirole Case Report Form GSK RRL100013

Engelsk

Exclusion Criteria 1 Ropinirole Case Report Form GSK RRL100013

1 Formulär  
Administrative documentation
Beskrivning

Administrative documentation

Study number
Beskrivning

Study number

Datatyp

integer

Alias
UMLS CUI [1]
C2826693
Subject Nr.:
Beskrivning

Clinical Trial Subject Unique Identifier

Datatyp

text

Alias
UMLS CUI [1]
C2348585
Panel ID:
Beskrivning

Panel ID

Datatyp

integer

Alias
UMLS CUI [1]
C3826248
Visit
Beskrivning

Visit

Datatyp

integer

Alias
UMLS CUI [1]
C0545082
Date
Beskrivning

DD/MON/YY

Datatyp

date

Alias
UMLS CUI [1]
C0011008
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
1. Does the subject have a definite or suspected personal history or family history of adverse reactions or hypersensitivity to the study drug or to drugs with a similar chemical structure?
Beskrivning

Adverse reaction to study drug

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0559546
UMLS CUI [1,2]
C0013175
2. Does the subject have a history or presence of clinically significant cardiovascular, neurological, psychiatric, haemotological or renal abnormalities?
Beskrivning

Abnormality of organs or blood

Datatyp

boolean

Alias
UMLS CUI [1]
C0243050
UMLS CUI [2]
C0027765
UMLS CUI [3]
C0004936
UMLS CUI [4]
C0475182
UMLS CUI [5]
C0151746
3. Does the subject have a history of postural hypotension or faints?
Beskrivning

Postural hypotension or faints

Datatyp

boolean

Alias
UMLS CUI [1]
C0020651
UMLS CUI [2]
C0039070
4. Does the subject have a history or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs?
Beskrivning

Gastrointestinal, hepatic or renal disease

Datatyp

boolean

Alias
UMLS CUI [1]
C0017178
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0022658
UMLS CUI [4]
C1512073
5. Has the subject received prescribed medication (including the oral contraceptive pill and hormone replacement therapy) within 14 days or over-the-counter (OTC) medicine within 7 days before the first dosing day, which in the opinion of the Principal Investigator may interfere with the study procedures or compromise a subject's safety?
Beskrivning

Subjects who have taken OTC medication (apart from CYP1A2 medications, see below) may still be entered into the study, if, in the opinion of the Principal/Co-investigator in agreement with the Sponsor, the medication received will not interfere with the study procedures or compromise subject1s safety.

Datatyp

boolean

Alias
UMLS CUI [1]
C3166216
UMLS CUI [2]
C0013231
UMLS CUI [3,1]
C4054723
UMLS CUI [3,2]
C0008972
6. Has the subject withdrawn, introduced, or changed the dose of any drug known to substantially inhibit CYP 1A2 (e.g., ciprofloxacin, fluvoxarnine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g., tobacco, omeprazole) within 7 days prior to first day of dosing?
Beskrivning

Drugs with effect on CYP1A2

Datatyp

boolean

Alias
UMLS CUI [1]
C1827490
UMLS CUI [2,1]
C0919438
UMLS CUI [2,2]
C0207509
Tillbaka till toppen

Similar models

Exclusion Criteria 1 Ropinirole Case Report Form GSK RRL100013

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Administrative documentation
Study number
Item
Study number
integer
C2826693 (UMLS CUI [1])
Clinical Trial Subject Unique Identifier
Item
Subject Nr.:
text
C2348585 (UMLS CUI [1])
Panel ID
Item
Panel ID:
integer
C3826248 (UMLS CUI [1])
Visit
Item
Visit
integer
C0545082 (UMLS CUI [1])
Date
Item
Date
date
C0011008 (UMLS CUI [1])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
Adverse reaction to study drug
Item
1. Does the subject have a definite or suspected personal history or family history of adverse reactions or hypersensitivity to the study drug or to drugs with a similar chemical structure?
boolean
C0559546 (UMLS CUI [1,1])
C0013175 (UMLS CUI [1,2])
Abnormality of organs or blood
Item
2. Does the subject have a history or presence of clinically significant cardiovascular, neurological, psychiatric, haemotological or renal abnormalities?
boolean
C0243050 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
C0004936 (UMLS CUI [3])
C0475182 (UMLS CUI [4])
C0151746 (UMLS CUI [5])
Postural hypotension or faints
Item
3. Does the subject have a history of postural hypotension or faints?
boolean
C0020651 (UMLS CUI [1])
C0039070 (UMLS CUI [2])
Gastrointestinal, hepatic or renal disease
Item
4. Does the subject have a history or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs?
boolean
C0017178 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C1512073 (UMLS CUI [4])
Subject's medication
Item
5. Has the subject received prescribed medication (including the oral contraceptive pill and hormone replacement therapy) within 14 days or over-the-counter (OTC) medicine within 7 days before the first dosing day, which in the opinion of the Principal Investigator may interfere with the study procedures or compromise a subject's safety?
boolean
C3166216 (UMLS CUI [1])
C0013231 (UMLS CUI [2])
C4054723 (UMLS CUI [3,1])
C0008972 (UMLS CUI [3,2])
Drugs with effect on CYP1A2
Item
6. Has the subject withdrawn, introduced, or changed the dose of any drug known to substantially inhibit CYP 1A2 (e.g., ciprofloxacin, fluvoxarnine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g., tobacco, omeprazole) within 7 days prior to first day of dosing?
boolean
C1827490 (UMLS CUI [1])
C0919438 (UMLS CUI [2,1])
C0207509 (UMLS CUI [2,2])
Tillbaka till toppen 

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial